ENG/中
老虎證券
行情
产品介绍
Cash Boost账户
新加坡股
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務
Pernix Therapeutics Holdings
0.2070
0.0000
成交量:
- -
成交額:
- -
市值:
300.27萬
市盈率:
-0.03
高:
0.2070
開:
0.2070
低:
0.2070
收:
0.2070
資料載入中...
總覽
公司
新聞
公告
公司資料
公司名字:
Pernix Therapeutics Holdings
交易所:
NASDAQ
成立時間:
- -
員工人數:
- -
公司地址:
- -
官網:
http://www.pernixtx.com
郵編:
- -
電話:
- -
傳真:
- -
簡介:
Pernix Therapeutics Holdings, Inc.於1996年11月8日在馬里蘭州註冊成立。公司是一家特種藥物生產企業,主要對一系列品牌及基因醫藥產品進行售賣、市場營銷、生產和研發,這些醫藥產品主要應用於失眠、細菌感染以及咳嗽和感冒癥狀。公司希望通過酌情把其產品推銷給內科醫生、衛生保健行業從業者以及顧客,以此來預見公司業績的持續增長。自成立之日起,公司便參与了多項併購重組以及許可證協議,以此希望擴大其產品銷售渠道。作為其部分擴張戰略,公司計劃對其他產品和公司進行戰略收購,同時研發並引進額外產品,其目的是將慢性、非季節性的特種產品引入到其利潤範圍中。其品牌產品包括先力騰(CEDAX),它是治療中耳炎的抗生素類藥物,同時也是治療咳嗽和感冒的處方藥(包括ZUTRIPRO, REZIRA和VITUZ)。公司還對多賽平(SILENOR)進行市場營銷,該物可以治療失眠症(對睡眠維持有困難),同時不受買賣控制。公司通過售賣及市場營銷組織宣傳其品牌藥物。
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/PTX/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTX\",,,,,undefined,":{"symbol":"PTX","market":"US","secType":"STK","nameCN":"Pernix Therapeutics Holdings","latestPrice":0.207,"timestamp":1552680000000,"preClose":0.207,"halted":0,"volume":0,"delay":0,"floatShares":13322183,"shares":14505848,"eps":-6.260195,"marketStatus":"未開盤","change":0,"latestTime":"03-15 16:00:00 EDT","open":0.207,"high":0.207,"low":0.207,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-6.260195,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1753344000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":855291600000,"exchange":"NASDAQ","adjPreClose":0.207,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PTX\",,,,,undefined,":{"symbol":"PTX","floatShares":13322183,"roa":"--","roe":"--","lyrEps":-7.205398,"shares":14505848,"dividePrice":0,"high":0.207,"amplitude":0,"preClose":0.207,"low":0.207,"week52Low":0.203,"pbRate":"-0.01","week52High":3.3,"institutionHeld":0.7448,"latestPrice":0.207,"eps":-6.260195,"divideRate":0,"volume":0,"delay":0,"ttmEps":-6.260195,"open":0.207,"prevYearClose":0.207},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.pernixtx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0568},{"period":"3month","weight":0.1601},{"period":"6month","weight":0.0432},{"period":"1year","weight":0.1452},{"period":"ytd","weight":0.0821}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Pernix Therapeutics Holdings, Inc.於1996年11月8日在馬里蘭州註冊成立。公司是一家特種藥物生產企業,主要對一系列品牌及基因醫藥產品進行售賣、市場營銷、生產和研發,這些醫藥產品主要應用於失眠、細菌感染以及咳嗽和感冒癥狀。公司希望通過酌情把其產品推銷給內科醫生、衛生保健行業從業者以及顧客,以此來預見公司業績的持續增長。自成立之日起,公司便參与了多項併購重組以及許可證協議,以此希望擴大其產品銷售渠道。作為其部分擴張戰略,公司計劃對其他產品和公司進行戰略收購,同時研發並引進額外產品,其目的是將慢性、非季節性的特種產品引入到其利潤範圍中。其品牌產品包括先力騰(CEDAX),它是治療中耳炎的抗生素類藥物,同時也是治療咳嗽和感冒的處方藥(包括ZUTRIPRO, REZIRA和VITUZ)。公司還對多賽平(SILENOR)進行市場營銷,該物可以治療失眠症(對睡眠維持有困難),同時不受買賣控制。公司通過售賣及市場營銷組織宣傳其品牌藥物。","exchange":"NASDAQ","name":"Pernix Therapeutics Holdings","nameEN":"Pernix Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PTX\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2018-11-08","symbol":"PTX","fiscalQuarterEnding":"2018/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1541653200000,"reportTimeType":"","actualEps":-0.89},{"market":"US","date":"2018-08-09","symbol":"PTX","fiscalQuarterEnding":"2018/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1533787200000,"reportTimeType":"","actualEps":-1.13},{"market":"US","date":"2018-05-10","symbol":"PTX","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1525924800000,"reportTimeType":"","actualEps":-1.57},{"market":"US","date":"2018-03-08","symbol":"PTX","fiscalQuarterEnding":"2017/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1520485200000,"reportTimeType":"","actualEps":-2.78},{"market":"US","date":"2017-11-07","symbol":"PTX","fiscalQuarterEnding":"2017/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1510030800000,"reportTimeType":"","actualEps":-0.57}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PTX\",market:\"US\",delay:false,,,undefined,":{}}}